← Human Trials & Peer-Reviewed Studies
Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial.
Plain-language guide to PMID 2105243 (1990): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in 16 women.
Key Facts
- PMID
- 2105243
- Journal
- Fertility and sterility
- Year
- 1990
- Study type
- Randomized Controlled Trial
- Authors
- Homburg R et al. (4 authors)
- DOI
- 10.1016/s0015-0282(16)53277-4
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in this randomized controlled trial publication.
A randomized, double-blind, placebo-controlled trial of cotreatment with biosynthetic, human sequence, growth hormone (GH), and human menopausal gonadotropins (hMG) for induction of ovulation was performed in 16 women with amenorrhea and anovulatory infertility.
Who Took Part
The study group was 16 women.
By PubMed's age tags, the people studied were adults, women only.
Those who received placebo were given GH in a subsequent course of treatment.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The women were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the women nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
What Was Measured
Topics PubMed links to this paper include Amenorrhea, Anovulation, Clinical Trials as Topic, Growth Hormone, Hypogonadism, Hypophysectomy and Infertility, Female.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in 16 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1990 (Fertility and sterility), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- HMG (Human Menopausal Gonadotropin) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.